Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-20 4:30 pm Purchase | 2025-11-13 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Paradigm BioCapital Advisors LP | 3,671,999 5.000% | 3,671,999 (New Position) | Filing History |
| 2025-11-14 4:17 pm Unchanged | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Longitude Capital Partners IV, LLC | 2,765,381 3.800% | 0 (Unchanged) | Filing History |
| 2025-11-14 4:00 pm Purchase | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Vestal Point Capital, LP | 4,117,302 7.500% | 889,141 (+27.54%) | Filing History |
| 2025-11-14 12:49 pm Purchase | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | JANUS HENDERSON GROUP PLC JHG | 6,105,527 11.300% | 2,421,144 (+65.71%) | Filing History |
| 2025-11-14 06:04 am Sale | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Balyasny Asset Management L.P. | 5,394,721 9.990% | -2,950,930 (-35.36%) | Filing History |
| 2025-11-07 4:42 pm Sale | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Integrated Core Strategies (US) LLC | 2,313,642 3.200% | -522,650 (-18.43%) | Filing History |
| 2025-10-27 4:07 pm Purchase | 2025-10-20 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | RA CAPITAL MANAGEMENT L.P. | 5,000,000 6.900% | 5,000,000 (New Position) | Filing History |
| 2025-10-17 6:13 pm Purchase | 2025-09-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | BlackRock Inc. BLK | 2,168,444 4.000% | 346,478 (+19.02%) | Filing History |
| 2025-08-14 4:58 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Citadel Advisors LLC | 5,334,112 9.600% | 3,249,845 (+155.92%) | Filing History |
| 2025-08-14 3:51 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Vestal Point Capital, LP | 3,228,161 6.000% | 3,228,161 (New Position) | Filing History |
| 2025-08-14 1:40 pm Sale | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Frazier Life Sciences Public Fund, L.P. | 3,073,467 5.700% | -2,427,345 (-44.13%) | Filing History |
| 2025-08-14 11:46 am Sale | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | JANUS HENDERSON GROUP PLC JHG | 3,684,383 11.100% | -873,537 (-19.17%) | Filing History |
| 2025-08-14 06:40 am Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Balyasny Asset Management L.P. | 8,345,651 9.990% | 8,345,651 (New Position) | Filing History |
| 2025-08-07 4:18 pm Purchase | 2025-06-30 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Integrated Core Strategies (US) LLC | 2,836,292 5.300% | 902,913 (+46.70%) | Filing History |
| 2025-06-04 4:51 pm Purchase | 2025-05-28 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Frazier Life Sciences Public Fund, L.P. | 5,500,812 9.900% | 5,500,812 (New Position) | Filing History |
| 2025-06-04 4:04 pm Purchase | 2025-05-28 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Affinity Healthcare Fund, LP | 4,252,005 7.750% | 4,252,005 (New Position) | Filing History |
| 2025-05-15 09:58 am Sale | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | D1 Capital Partners L.P. | 978,652 2.900% | -1,527,955 (-60.96%) | Filing History |
| 2025-05-14 12:00 pm Purchase | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | JANUS HENDERSON GROUP PLC JHG | 4,557,920 13.700% | 218,666 (+5.04%) | Filing History |
| 2025-05-13 06:55 am Purchase | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Mizuho Financial Group, Inc. | 2,203,631 6.600% | 276,700 (+14.36%) | Filing History |
| 2025-05-12 09:00 am Sale | 2025-03-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Adage Capital Management, L.P. | 237,953 0.700% | -1,971,662 (-89.23%) | Filing History |